Chowdhury, G M I
Zhang, J
Thomas, M
Banasr, M
Ma, X
Pittman, B
Bristow, L
Schaeffer, E
Duman, R S
Rothman, D L
Behar, K L
Sanacora, G
Article History
Received: 8 September 2015
Revised: 13 January 2016
Accepted: 11 February 2016
First Online: 12 April 2016
Competing interests
: Dr Sanacora has received consulting fees from AstraZeneca, Avanier Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly & Co., Hoffman La-Roche, Merck, Navigen, Naurex, Noven Pharmaceuticals, Servier Pharmaceuticals, Takeda, Teva and Vistagen therapeutics over the past 24 months. He has also received additional research contracts from AstraZeneca, Bristol-Myers Squibb, Eli Lilly & Co., Johnson & Johnson, Hoffman La-Roche, Merck & Co., Naurex and Servier over the past 24 months. Free medication was provided to Dr Sanacora for an NIH-sponsored study by Sanofi-Aventis. In addition, he holds shares in BioHaven Pharmaceuticals Holding Company and is a coinventor on a US patent (no. 8 778 979) held by the Yale University. Dr Duman has received consulting fees from Taisho, Naurex, Sunovion and Johnson & Johnson, and investigator-initiated grants from Forest, Naurex, Sunovion and Eli Lilly & Co. Dr Bristow is an employee of Bristol-Myers Squibb. Dr Schaeffer was an employee of Bristol-Myers Squibb at the time the research was completed and is currently an employee of Janssen Research and Development. Dr Banasr has received research contracts from BioHaven Pharmaceuticals and Servier Pharmaceuticals. Dr Behar holds common stock in Pfizer. The remaining authors declare no conflicts of interest.